ArticleFrontiers in oncology2022

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma.

Saba S Shaikh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.